Clinical Trial 44343

Long Beach, CA 90806


The purpose of this study is to characterize the efficacy and safety of evobrutinib 45 mg administered orally twice daily versus teriflunomide (Aubagio®; 14 mg once a day orally) in participants with relapsing multiple sclerosis (RMS).

Qualified Participants Must:

• Be 18-55 years old
• Be diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or SPMS with relapses)
• One or more documented relapses within the 2 years before Screening
Additional criteria applies, please contact the site for full details.

Qualified Participants May Receive:

Compensation of up to $4,375 for time, complimentary transportation and meals, no cost study-related treatments and medications.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.